About the Parkinson’s
Progression Markers Initiative
The Parkinson’s Progression Markers Initiative is a landmark
observational clinical study to better understand the progression
of Parkinson’s disease. The goal of PPMI is to identify and assess
biomarkers, or indicators, of Parkinson’s disease. The discovery of
a PD biomarker is critical to the development of new and better
treatments for PD, particularly treatments that could slow or stop
the progression of the disease, something no currently available
treatment can do.
PPMI is the first clinical study to assemble a population large
enough in size to draw meaningful scientific conclusions over time
to develop better ways to measure the progression of Parkinson’s
disease. PPMI is a worldwide effort, with 32 study sites across
the United States, Europe, Australia, and the Middle East.
It is sponsored byThe Michael J. Fox Foundation for
Parkinson’s Research.
www.ppmi-info.org
33